Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Surgery. 2012 Aug;152(2):277–285. doi: 10.1016/j.surg.2012.05.006

Figure 1. PIK3CA and KRAS siRNAs most effectively inhibit CRC proliferation.

Figure 1

(A) HCT116 and (B) DLD-1 human colon cancer cells were plated in 24 well plates at a density of 25,000 cells/well. Cells were transfected 12 h later with a panel of single siRNAs directed to the PI3K/AKT/mTOR (PIK3R1, PIK3CA, AKT1, AKT2, RICTOR, RAPTOR) or RAS (KRAS, BRAF, MEK1, MEK2, ERK1, ERK2) pathways. Proliferation was assessed by cell counting at 72 h. Results for selected siRNA treatments are shown (* p < 0.05 vs. control).